Remove Manufacturing Remove Safety Remove Side effects
article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

2,3 Clinical implementation of CAR T-cell technology requires a reproducible T-cell manufacturing platform, which necessitates effective gene-transfer tools and T-cell culture conditions. After this incident CAR-related toxicity scales and guidelines were established to prevent adverse reactions.

article thumbnail

First CRISPR-based gene-editing therapy authorised

European Pharmaceutical Review

Side effects from treatment were similar to those associated with autologous stem cell transplants. No significant safety concerns were identified during the trials. Of these, 39 did not need a red blood cell transfusion for at least 12 months post-treatment.

Safety 114
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

UK MHRA grants authorisation for Moderna’s Covid-19 booster vaccine

Pharmaceutical Technology

After the vaccine was found to meet the standards of safety and quality, the regulatory agency granted the authorisation. According to the safety monitoring, side effects were generally mild and self-resolving, as well as in line with those reported for the original Moderna booster dose. 1 Omicron variant of concern.

article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal side effects. Manufacturing Optimization While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology.

Pharma 95
article thumbnail

The internet enables misinformation on COVID

World of DTC Marketing

In some instances, vaccine-hesitant activists are manufacturing stories of deaths related to the vaccine that never happened. The major concerns for hesitancy included worries over side effects and that the vaccine is too new. Also cited was a lack of trust in the government to ensure the vaccines’ safety and effectiveness.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

However, disease heterogeneity has limited the field’s understanding of lupus, and the regulatory requirements for manufacturing and developing cell therapies have proven to be a hurdle. “[The] The CAR-T therapies for conditions like lupus continue to look promising, but their safety is a concern, says Gilkeson.

article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

At week 28, the study assessed the vaccine’s safety and levels of anti-HBV surface antibodies (HBsAbs). The most common side effects related to vaccination were injection site pain, malaise, fatigue, muscle aches and headaches. The international study will continue to examine the effects of two-dose HEPLISAV-B.